A caerulein-sensitive potentiation of the behavioral effects of apomorphine by dibutyryl-cAMP.
The dopaminergic behavioral effects of apomorphine in rats were evaluated using a rating scale. Caerulein, a decapeptide physiologically similar to cholecystokinin, enhanced at lower doses and inhibited at higher doses the behaviors induced by apomorphine. Dibutyryl-cAMP, but not dibutyryl-cGMP, potentiated apomorphine behaviors. This potentiation was inhibited by a high dose of caerulein. These data provide evidence for an opposing effect of cAMP and caerulein or cholecystokinin in modulating dopaminergic systems.
D000818:Animals; D001058:Apomorphine / Q000008:administration & dosage*; D003994:Bucladesine / Q000008:administration & dosage*; D002108:Ceruletide / Q000008:administration & dosage*; D002766:Cholecystokinin / Q000008:administration & dosage; D003995:Dibutyryl Cyclic GMP / Q000008:administration & dosage; D007276:Injections, Intraventricular; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains
D003995:Dibutyryl Cyclic GMP; D003994:Bucladesine; D002108:Ceruletide; D002766:Cholecystokinin; D001058:Apomorphine